FDA: First Generic Estradiol Levonorgestrel Patch Approved

• The FDA has approved the first generic version of Climara Pro, an estradiol and levonorgestrel transdermal system.
• Zydus Pharmaceuticals (USA) Inc. is the manufacturer of this once-weekly hormone therapy patch.
• This generic estradiol and levonorgestrel transdermal system is therapeutically equivalent to Climara Pro and is indicated for women with an intact uterus.
• The approval supports the FDA's goal of increasing access to affordable medications and fostering market competition.
• The patch contains both estrogen and progestogen to reduce the risk of endometrial hyperplasia in women with an intact uterus.

The introduction of generic alternatives like the estradiol and levonorgestrel transdermal system is instrumental in driving down costs and making treatments more accessible to a wider patient population.

The U.S. Food and Drug Administration (FDA) recently announced the approval of the first generic version of Climara Pro, a significant development for women's health. This new estradiol and levonorgestrel transdermal system, developed by Zydus Pharmaceuticals (USA) Inc., offers a once-weekly transdermal hormone therapy patch. The original Climara Pro, a registered trademark of Bayer, delivers 0.045 mg per day of estradiol and 0.015 mg of levonorgestrel.

This FDA approves generic estradiol levonorgestrel patch decision marks a crucial step in expanding access to essential medications. Acting FDA Commissioner Kyle Diamantas, J.D., emphasized that menopause is a universal experience that profoundly impacts quality of life, and this approval directly enhances the accessibility of effective treatment options. The agency's action underscores its ongoing commitment to ensuring American patients have access to safe, affordable, and high-quality medications.

The newly approved Zydus Pharmaceuticals estradiol levonorgestrel transdermal system has been deemed therapeutically equivalent to its brand-name counterpart, Climara Pro. This means it is expected to have the same clinical effect and safety profile when administered to patients. The patch is specifically indicated for women who have an intact uterus, a critical detail due to its unique formulation.

Unlike estrogen-only patches commonly used in menopause management, this FDA generic hormone therapy product contains both estrogen and progestogen in a single patch. The inclusion of progestogen is vital for women with an intact uterus, as it helps to mitigate the risk of endometrial hyperplasia, a condition that can arise from estrogen use alone. Michael Davis, M.D., Ph.D., Director of FDA's Center for Drug Evaluation and Research, also highlighted the practical advantage of once-weekly dosing, noting that it can significantly improve how patients manage their care and potentially enhance adherence compared to daily oral medications.

This Climara Pro generic approval aligns directly with the FDA’s Public Health Pillar focused on increasing access to affordable medicines and medical products. The agency's broader strategy, known as the FDA Drug Competition Action Plan, aims to foster a more competitive pharmaceutical market. Historically, generic drugs account for a vast majority of prescriptions filled in the U.S., with nine out of ten prescriptions being for generics.

The introduction of generic alternatives like the estradiol and levonorgestrel transdermal system is instrumental in driving down costs and making treatments more accessible to a wider patient population. By promoting competition, the FDA seeks to ensure that more patients can afford the medications they need, thereby improving overall public health outcomes. However, it is important for patients and healthcare providers to be aware of the contraindications, which include undiagnosed abnormal genital bleeding, breast cancer, estrogen-dependent neoplasia, active or historical thromboembolic diseases, known hypersensitivity to the components, hepatic impairment, and certain thrombophilic disorders. Common adverse reactions reported in clinical trials (occurring in 5% or more of patients) include application site reactions, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache, and flu syndrome.

Pharmaceutical companies and their legal counsel should note this approval as it signifies increased market competition for hormone therapy products and aligns with the FDA's stated goal of expanding access to affordable generic medications, potentially impacting future drug development, pricing strategies, and regulatory submissions for similar products.

Source: Original reporting via FDA press release